This open-label extension study of Ace-ER will assess the long-term safety and efficacy of Ace-ER treatment over a period of 24 months. Approximately 165 subjects from the UX001-CL202, UX001-CL301 and UX001-CL203 studies will be eligible to enroll in the study.